EP
CORT icon

Edgestream Partners’s Corcept Therapeutics CORT Stock Holding History

Edgestream Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-69,217
Closed -$2.79M – 987
2026
Q1 		$2.79M Buy
+69,217
New +$2.59M 0.09% 404
2025
Q2 		– Sell
-64,009
Closed -$7.31M – 876
2025
Q1 		$7.31M Buy
+64,009
New +$3.9M 0.25% 112
2024
Q3 		– Sell
-23,516
Closed -$764K – 873
2024
Q2 		$764K Sell
23,516
-36,775
-61% -$1.01M 0.04% 584
2024
Q1 		$1.52M Buy
+60,291
New +$1.42M 0.08% 406
2023
Q3 		– Sell
-28,788
Closed -$641K – 836
2023
Q2 		$641K Buy
+28,788
New +$663K 0.06% 474

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Edgestream Partners's CORT Position: Q2 2026 in Review

Edgestream Partners sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 69,217 shares — an estimated $2.79M sold.

Edgestream Partners first reported a position in CORT in Q2 2023 and held it in 5 quarters. The position peaked at $7.31M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Edgestream Partners reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Edgestream Partners sold 69,217 Corcept Therapeutics shares in Q2 2026, an estimated $2.79M.
  • Edgestream Partners first reported a position in Corcept Therapeutics in Q2 2023 and held it in 5 quarters.
  • Edgestream Partners's Corcept Therapeutics position peaked at $7.31M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.